ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕

Blog

  • Home
  • Blog
✕

FIND US

CATEGORIES

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

LATEST POSTS

  • 1
    Five ways to enhance the impact of cancer research advocacy across ECOG‑ACRIN: Lisa Beckendorf discusses insights from recent interviews with research leaders
    May 14, 2026
  • 0
    Now Enrolling: The EA6232 research study is testing a broccoli-derived supplement to help prevent melanoma from coming back
    May 14, 2026

RECENT COMMENTS

  • May 28, 2026

    ECOG-ACRIN Staff commented on Ongoing Trial: For patients with advanced or rare cancers, NCI-MATCH may offer a treatment option

  • May 15, 2026

    Bobbi Caron commented on Ongoing Trial: For patients with advanced or rare cancers, NCI-MATCH may offer a treatment option

TAGS

Advocacy Anal cancer Artificial intelligence (AI) Bladder cancer Brain cancer Breast cancer Colorectal cancer ComboMATCH Esophagus cancer Gallbladder cancer Head and neck cancer Health equity Immunotherapy In memory Kidney cancer Leukemia Liver cancer Lung cancer Lymphoma Mammography Melanoma Myelodysplastic syndrome Myeloma NCI-MATCH Older adults Pancreatic cancer Pancreatic cysts Patient-reported outcomes Patient education Patient navigation Penis cancer Personalized treatment Policy Precision medicine Prevention Prostate cancer Real-world data/evidence Research results Sarcoma Screening for cancer Side effects Survivorship Targeted therapy Upper tract urothelial cancer Young adults

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc